Dublin, June 13, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Active Pharmaceutical Ingredients Global Market - Forecast to 2022" report to their offering.
The global API market is segmented based on synthesis, customer base, business type and therapeutic applications. Depending on synthesis the market is classified into synthetic chemical API, biotech API and HPAPI (Highly Potent Active Pharmaceutical Ingredient). Biotech API is further segmented into mammalian cell culture, monoclonal antibodies, recombinant proteins, vaccines, insulin analog, growth hormones and interferons.
Mammalian cell culture accounted for the largest share in 2013, while monoclonal antibody segment is the fastest growing segment by 2020. Despite low production yields, high manufacturing cost and highly unstable cell culturing method mammalian culture is the largest due to post-translational mechanism present in living cells. Monoclonal antibodies are growing at a faster pace due to demand for biotech APIs and increasing venture capital investments that drives the market.
By-customer base the API market is segmented into synthetic chemicals API, biotech API and HPAPI. Synthetic chemical API is further classified into branded/innovative and generic/non-branded API. Branded API accounted for the largest share whereas, generic is the fastest growing segment. Biotech API is further divided into biologics and biosimilars where biologics accounted for the largest share.
Depending on business type the API market is segmented into captive and merchant. Captive market accounted for the largest revenue in 2013. Based on the therapeutic applications the global API market is categorized into eleven crucial application areas such as anti-infectives, oncology, cardiovascular and hematopoietic system, central nervous system, gastrointestinal disorder, respiratory system, hormonal-related disorder, metabolic disorder, genito-urinary disorder, musculo-skeletal disorder and others.
Anti-infectives segment dominated the application market with a largest in 2013 whereas oncology segment is the fastest growing segment with a CAGR of approximately 8% by 2020. Patent expiration of major drugs, increased incidence of various cancer diseases and aged population, high government investments for cancer research and healthcare awareness are the factors that drives the market whereas stringent regulations, failure of crucial drugs in last stage of clinical trial, and economical crisis are the factors that hampers the market growth.
Major players in the API market include Teva Active Pharmaceutical Industries Limited (Israel), Ranbaxy Laboratories (India), Dr. Reddy's Lab (India), Boehringer Ingelheim GmbH (Germany), Lonza group (Switzerland), Lupin (India), Novartis (Switzerland), Aurobindo pharma (India), and Albemarle Corporation (U.S.).
Key Topics Covered:
1 Executive Summary
2 Introduction
3 Market Analysis
4 Global API Market Overview
5 Global API Market, By Therapeutic Application
6 Regional Market Analysis
7 Company Developments
8 Major Player Profiles
Companies Mentioned
- Aarti Drugs Ltd
- Abbvie
- Actavis Pharmaceuticals
- Ajantha Pharma
- Akorn
- Albany Molecular Research Inc (Amri)
- Alembic Ltd
- Amneal Pharmaceuticals Llc
- Apotex Fermentation Inc
- Aqvida Gmbh
- Arena Pharmaceuticals
- Arevipharma Gmbh
- Ariston Pharma Novatech Pvt Ltd
- Aurobindo Pharma
- Basf
- Bayer Pharma Chemicals
- Biocon Ltd
- Biodel Corporation
- Biosortia Pharmaceuticals
- Boehringer Ingelheim Gmbh
- Bristol-Myers Squibb
- Cadila Pharmaceuticals Limited
- Cambrex Corporation
- Catalent
- Century Pharmaceuticals Ltd
- Cepia Sanofi
- Cipla Limited
- Ckd Bio
- Corden Pharma
- Ctx Lifesciences
- Daiichi Sankyo Chemical Pharma Co Ltd
- Dishman Pharmaceuticals
- Dr.ReddyâS Laboratories
- Eirgen Pharma
- Emcure Pharmaceuticals Ltd
- Fermion
- Florentis Pharmaceuticals Pvt Ltd
- Global Merchants
- Heni Chemical Industries
- Indena
- Janssen Pharmaceutica Nv
- Kosher Pharmaceuticals
- Krka Pharmaceuticals
- Lannett
- Lilly Pharmaceuticals
- Liptis Pharmaceuticals
- Lonza Group
- Lupin
- Mallinckrodt Pharmaceuticals
- Medichem
- Megafine Pharma Ltd
- Merck Millipore
- Molcan
- Morepen
- Mylan N.V
- Nacto Pharma
- Nanomedex Pharmaceuticals
- Novartis Ag
- Novasep
- Novo Nordisk
- Oncobiologics
- Orchid Chemicals & Pharmaceuticals Ltd
- Perrigo
- Pfizer
- Pierre Fabre
- Princeton Biomolecular Research, Inc
- Python Biotech Llc
- Rablon Healthcare Pvt Ltd
- Reva Pharma Pvt Ltd
- Rpg Life Sciences
- Saamya Biotech
- Sandoz International Gmbh
- Saneca Pharmaceuticals
- Sanofi
- Salix Pharmaceuticals
- Scinopharm
- Shasun
- Shreeji Pharma International
- Sigma-Aldrich
- Sterling Biotech Ltd
- Sun Pharmaceutical Industries Ltd
- Surfachem
- Suven Life Science Ltd
- Symbiotec
- Takeda
- Taro Pharmaceuticals
- Teva Pharmaceuticals
- Trifecta Pharmaceuticals
- Welt Care Lifesciences Pvt Ltd
- Wockhardt
- Xellia Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/93rhpf/active